ASCO 2019 Annual Meeting
ASCO 2019 Prostate Cancer
- ASCO 2019: A Multicentric Phase II Randomized Trial of Docetaxel plus Enzalutamide versus Docetaxel as First-line Chemotherapy for Patients with Metastatic Castration-resistant Prostate Cancer: CHEIRON Study
- ASCO 2019: Updated Approaches to Treatment Sequencing in the Era of M0 CRPC Approvals
- ASCO 2019: Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy in Men with Clinically Localized, High-Risk Prostate Cancer - CALGB 90203 (Alliance)
- ASCO 2019: Clinical and Safety Outcomes of TALAPRO-2: A Two-part Phase III Study of Talazoparib in Combination with Enzalutamide in Metastatic Castration-resistant Prostate Cancer
- ASCO 2019: Predictive Biomarkers in Prostate Cancer
ASCO 2019 Bladder Cancer
- ASCO 2019: Vofatamab in Combination with Pembrolizumab in WT Metastatic Urothelial Carcinoma: FIERCE-22
- ASCO 2019: Targeted Therapeutics and Patient Selection in Advanced Urothelial Carcinoma
- ASCO 2019: Clinical Outcomes According to PD-L1 Status and Age in the Prospective International SAUL Study of Atezolizumab for Locally Advanced or Metastatic Urothelial Carcinoma or Non-UC of the Urinary Tract
- ASCO 2019: Pembrolizumab for Patients with High-Risk Non–Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin: Updated Follow-Up from KEYNOTE-057
- ASCO 2019: Comprehensive Genomic Profiling of Upper-Tract and Bladder Urothelial Carcinoma Reveals Opportunities for Therapeutic and Biomarker Development
ASCO 2019 Kidney Cancer
- ASCO 2019: IMmotion151 Subgroup Analysis: Atezolizumab + Bevacizumab versus Sunitinib in Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Histology
- ASCO 2019: CheckMate 214 Post-Hoc Analyses of Nivolumab plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma with Sarcomatoid Features
- ASCO 2019: Efficacy of Immune Checkpoint Inhibitors and Genomic Characterization of Sarcomatoid and/or Rhabdoid Metastatic Renal Cell Carcinoma
- ASCO 2019: Patient-Reported Outcomes in IMmotion150: Atezolizumab alone or with Bevacizumab versus Sunitinib in First-Line Metastatic Renal Cell Carcinoma
- ASCO 2019: Sarcomatoid RCC: Defining a New Treatment Paradigm?
ASCO 2019 Press Releases
- Janssen Seeks to Expand Use of ERLEADA® (apalutamide) in the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer
- Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
- ASCO 2019: TITAN: Apalutamide Meets Dual Primary Endpoints, Shows Good Tolerability in Metastatic Hormone Sensitive Prostate Cancer
- ASCO Announces Top Studies to Be Presented at 2019 Annual Meeting
- Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting
